Pharmaceutical companies have resorted to different ways to address the challenges posed by the COVID-19 pandemic with respect to supply chain risks including diversification of suppliers and sources.
GlobalData has conducted a survey to assess how companies addressed and monitored import/export and supply chain risks associated with coronavirus in the first and third quarters.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Monitoring of import/export and supply chain risks related to coronavirus: Q1 vs Q3
A majority 45% of the companies in Q1 opined that they do not have a dedicated team to address the risks, but they have committees/working teams that meet up regularly. The percentage declined marginally to 44% in Q3.
A dedicated team was available to address the risks at 38% of the companies in Q1, which declined to 35% in Q3.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDependence on suppliers to identify the risks increased, from approximately 17% of the companies in Q1 to 21% in Q3.
The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.
